查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1429268

法布瑞氏症治疗市场:现况分析与预测（2023-2030）

Fabry Disease Treatment Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于肥胖盛行率不断增加，法布瑞氏症治疗市场预计将稳定成长约 7.1%，而肥胖在法布瑞氏症的进展中扮演重要角色。 例如，根据《2022 年世界肥胖地图集》，预计到 2030 年，全球将有 10 亿人（五分之一的女性和七分之一的男性）患有肥胖症。 已经引入了许多新疗法来治疗这些遗传性疾病。 其他几个因素，例如人口中遗传性疾病数量的增加，正在以稳定的速度推动法布瑞氏症治疗市场。 例如，根据世界卫生组织 (WHO) 的数据，所有活产婴儿中约有 2-5% 患有遗传性疾病和先天性畸形。

依给药方式，市场分为口服给药部分及静脉给药部分。 2022年全球法布瑞氏症治疗市场中，口服用药将占最大份额。 由于患者对口服药物的需求不断增加，该细分市场占据了市场主导地位。 据报道，片剂因其高效的成分和易于食用而成为所有剂型中消耗最多的固体形式。 口服给药正在推动这一领域的成长，因为它对消费者来说更方便且更便宜。 因此，由于上述原因，口服製剂将在2022年占据较大的市场份额。

根据治疗，市场分为底物减少疗法、酵素替代疗法、伴侣疗法等。 由于其有效的治疗效果，酵素替代疗法预计将在预测期内占据主要份额。 Fabrazyme 可恢復 ALPHA-半乳糖甘□ A 的水平，从而分解体内的脂质并减轻法布瑞氏症的症状。 例如，根据2023年8月法布瑞氏症新闻报道，酵素替代疗法已被证明对法布瑞氏症患者非常有帮助。 除此之外，快速诊断测试的使用激增也推动了该领域的成长。 因此，预计酵素替代疗法类别在预测期内的应用中将表现出较高的复合年增长率。

为了更了解法布瑞氏症治疗的市场介绍，市场为北美（美国、加拿大等北美地区）、欧洲（德国、英国、法国、西班牙、义大利等欧洲地区） 、亚太地区（中国、中国和其他地区）。、日本、印度、亚太地区其他地区）和世界其他地区。 由于遗传性疾病的增加、法布瑞氏症患者数量的增加以及开发有效治疗方法的投资增加，北美在 2022 年将主导全球法布瑞氏症治疗市场。 例如，根据美国国家法布瑞氏症基金会的数据，目前美国法布瑞氏症基因带因者人数到2023年将超过11,000人。 政府机构已启动提高认识计划，以预防这些遗传性神经系统疾病，并为患者提供有效的护理。 因此，2022年北美将占据很大的市场份额。

目录

第一章市场介绍

  • 市场定义
  • 主要目标
  • 利害关係人
  • 限制

第二章研究方法或假设

  • 调查过程
  • 调查方法
  • 受访者简介

第三章市场总结

第 4 章执行摘要

第五章 COVID-19 对法布瑞氏症治疗市场的影响

第 6 章法布瑞氏症治疗市场收入，2020-2030

第 7 章依管理方法划分的市场洞察

  • 口头
  • 静脉注射

第 8 章按处理方式进行的市场洞察

  • 底物减少疗法
  • 酵素替代疗法
  • 陪伴疗法
  • 其他

第 9 章按地区划分的市场洞察

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区

第10章法布瑞氏症治疗市场动态

  • 市场驱动因素
  • 市场挑战
  • 影响分析

第11章法布瑞氏症治疗市场机会

第十二章法布瑞氏症治疗市场趋势

第十三章需求方与供给方分析

  • 需求方分析
  • 供给面分析

第14章价值链分析

第15章竞争场景

  • 竞争状况
    • 波特五力分析

第十六章公司简介

  • Pfizer Inc.
  • Merck KGaA
  • Sanofi
  • Biocare Medical, LLC
  • Lilly
  • Teva Pharmaceutical Industries Ltd.
  • MITSUBISHI CHEMICAL GROUP CORPORATION
  • Bristol-Myers Squibb Company
  • GSK plc.
  • Bayer AG

第十七章免责声明

简介目录
Product Code: UMHE212562

Fabry disease is a rare genetic disorder caused by the deficiency of an enzyme called alpha-galactosidase A. This deficiency leads to the accumulation of certain fatty substances in the body, affecting various organs and systems. Symptoms often start in childhood or adolescence and can include pain, skin lesions, gastrointestinal issues, and problems with the heart, kidneys, and nervous system. Early diagnosis and management are crucial to help alleviate symptoms and prevent complications. Fabry disease treatment is gaining prominence in the market owing to the increasing prevalence of fabry disease, rising cases of obesity, and rising demand for oral drugs. For instance, according to the National Institute of Health, classic fabry disease mutations are seen in approximately 1 in 30,000 males, and atypical presentations are associated with about 1 in 15,000 males and 1 in 23,000 females. Several factors, including a surge in the increasing awareness regarding inherited disorders, an increasing geriatric population, and increased investments from the government, public, and private sectors in healthcare departments are driving the growth of the market during the forecast period. According to the World Health Organization (WHO), the share of people aged above 60 will rise to 1.4 billion by 2030 while this share will increase to 2.1 billion by 2050 which would be more than double the share of the geriatric population in the year 2020 i.e., 1 billion.

The Fabry Disease Treatment Market is expected to grow at a steady rate of around 7.1% owing to the increased prevalence of obesity which plays an important role in the progression of fabry disease. For instance, as per the World Obesity Atlas 2022, estimations are such that 1 billion people worldwide, comprising one in five women and one in seven men will be suffering from obesity by the year 2030. Many new therapies are being introduced for treating these inherited disorders. Several other factors, such as rising genetic disorders among people are also driving this market of fabry disease treatment at a steady rate. For instance, according to the World Health Organization, genetic disorders and congenital abnormalities occur in about 2-5% of all live births.

Based on the mode of administration, the market is bifurcated into oral and intravenous segments. The oral segment held the maximum share in the global market of fabry disease treatment in 2022. This segment dominated the market because of the rising demand for oral drugs among patients. Tablets are reported to be the most consumed solid dosage forms among all medication forms, because of their highly effective composition, and ease of consumption. The oral mode of drug administration is much more convenient and easy on pockets for consumers, boosting this segment's growth. Hence, the oral segment held a significant share of the market in 2022 due to the above reasons.

Based on treatment, the market is categorized into substrate reduction therapy, enzyme replacement therapy, chaperone treatment, and others. The enzyme replacement therapy segment is expected to hold a significant share of the market in the forecast period owing to the efficient results of the therapy. Fabrazyme restores levels of alpha-galactosidase A. This allows the body to break down lipids and relieve the symptoms of fabry disease. For instance, according to Fabry Disease News in August 2023, enzyme replacement therapy has proved to be extremely helpful to fabry patients. Apart from this, the surge in the usage of rapid diagnostic tests is also impelling the growth of this segment. Hence, the enzyme replacement therapy category is expected to witness a higher CAGR during the forecast period amongst applications.

For a better understanding of the market adoption of fabry disease treatment, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the global fabry disease treatment market in 2022 due to the increasing genetic disorders, increased fabry disease cases, and rising investments in developing effective therapeutics. For instance, according to the National Fabry Disease Foundation, the number of individuals carrying the Fabry disease gene in the U.S. at over 11,000 according to currently published statistics of 2023. Government organizations are initiating awareness programs to prevent these inherited neurological disorders and provide efficient care to patients. Thus, North America held a significant share of the market in the year 2022.

Some of the major players operating in the market include Pfizer Inc.; Merck KGaA; Sanofi; Biocare Medical, LLC; Lilly; Teva Pharmaceutical Industries Ltd.; MITSUBISHI CHEMICAL GROUP CORPORATION; Bristol-Myers Squibb Company; GSK plc.; Bayer AG.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Fabry Disease Treatment Market
  • 2.2. Research Methodology of the Fabry Disease Treatment Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE FABRY DISEASE TREATMENT MARKET

6 FABRY DISEASE TREATMENT MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY MODE OF ADMINISTRATION

  • 7.1. Oral
  • 7.2. Intravenous

8 MARKET INSIGHTS BY TREATMENT

  • 8.1. Substrate Reduction Therapy
  • 8.2. Enzyme Replacement Therapy
  • 8.3. Chaperone Treatment
  • 8.4. Others

9 MARKET INSIGHTS BY REGION

  • 9.1. North America
    • 9.1.1. U.S.
    • 9.1.2. Canada
    • 9.1.3. Rest of North America
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. U.K.
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Rest of Asia-Pacific
  • 9.4. Rest of World

10 FABRY DISEASE TREATMENT MARKET DYNAMICS

  • 10.1. Market Drivers
  • 10.2. Market Challenges
  • 10.3. Impact Analysis

11 FABRY DISEASE TREATMENT MARKET OPPORTUNITIES

12 FABRY DISEASE TREATMENT MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 13.1. Demand Side Analysis
  • 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

  • 15.1. Competitive Landscape
    • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

  • 16.1. Pfizer Inc.
  • 16.2. Merck KGaA
  • 16.3. Sanofi
  • 16.4. Biocare Medical, LLC
  • 16.5. Lilly
  • 16.6. Teva Pharmaceutical Industries Ltd.
  • 16.7. MITSUBISHI CHEMICAL GROUP CORPORATION
  • 16.8. Bristol-Myers Squibb Company
  • 16.9. GSK plc.
  • 16.10. Bayer AG

17 DISCLAIMER